Lv21
178 积分 2023-08-03 加入
Endpoint Exposure‐Response Analyses in the Presence of Concurrent Dose Modification During Clinical Trials
1小时前
已完结
Strategies for successful dose optimization in oncology drug development: a practical guide
2个月前
已完结
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer
2个月前
已完结
Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition‐Survival Modeling Framework
2个月前
已完结
Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers
3个月前
已完结
Dose-reduction of bevacizumab in atezolizumab plus bevacizumab therapy extends treatment duration with disease control in patients with hepatocellular carcinoma
3个月前
已关闭
Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition‐Survival Modeling Framework
4个月前
已完结
Practical guide to concentration-QTc modeling: a hands-on tutorial
4个月前
已完结
Enzymatic hydrolysis of acyl glucuronide metabolites in human liver microsomes correlates to the risk of idiosyncratic drug toxicity
6个月前
已完结
Driving to a Better Understanding of Acyl Glucuronide Transformations Using NMR and Molecular Modeling
6个月前
已完结
皖公网安备34019202002308
